For adults with heart disease and obesity who don’t have diabetes, taking a weekly semaglutide shot (2.4 mg) leads to more than twice as many people stopping treatment because of side effects...

In obese adults without diabetes but with heart disease, weekly injections of semaglutide at 2.4 mg led to a higher rate of patients stopping treatment because of side effects compared to those receiving a placebo.

A weekly injection of semaglutide (2.4 mg) helps lower the risk of serious heart problems like heart attack, stroke, or heart-related death by 20% in people over 45 who have heart disease and are overweight, but don’t have diabetes, compared to a fake treatment.

In adults over 45 with heart disease and obesity but no diabetes, a weekly injection of semaglutide at 2.4 mg for about 3.3 years lowers the combined risk of heart-related death, heart attack, or stroke compared to a placebo.

Even if you don’t have diabetes, if you’re overweight and have heart disease, a weekly shot of semaglutide can cut your risk of heart attack or stroke by 1 in 5 — and this benefit starts before you lose much weight.

For people with heart disease, taking semaglutide means about 1 in 12 will stop treatment because of stomach problems like nausea or diarrhea — much more common than with a dummy pill.